Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms

Ohishi, Yoshihiro; Oda, Yoshinao; Kurihara, Shuichi; Kaku, Tsunehisa; Yasunaga, Masafumi; Nishimura, Isao; Okuma, Emi; Kobayashi, Hiroaki; Wake, Norio; Tsuneyoshi, Masazumi

doi:10.1016/j.humpath.2009.01.002

Cited by 11 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clear cell adenocarcinoma may exhibit papillary histology similar to that of serous adenocarcinomas, 25,26 and serous borderline tumors may have hob-nail-like cells mimicking clear cell adenocarcinoma pathology. 27 Endometrioid neoplasms may also contain clear cells; 28 thus, a differential diagnosis between clear cell adenocarcinoma and other histological subtypes is necessary. Some yolk sac tumors also show similar histology to clear cell adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Napsin A is a specific marker for ovarian clear cell adenocarcinoma

et al. 2015

View full text Add to dashboard Cite

Ovarian clear cell adenocarcinoma has a relatively poor prognosis among the ovarian cancer subtypes because of its high chemoresistance. Differential diagnosis of clear cell adenocarcinoma from other ovarian surface epithelial tumors is important for its treatment. Napsin A is a known diagnostic marker for lung adenocarcinoma, and expression of napsin A is reported in a certain portion of thyroid and renal carcinomas. However, napsin A expression in ovarian surface epithelial tumors has not previously been examined. In this study, immunohistochemical analysis revealed that in 71 of 86 ovarian clear cell adenocarcinoma patients (83%) and all of the 13 patients with ovarian clear cell adenofibroma, positive napsin A staining was evident. No expression was observed in 30 serous adenocarcinomas, 11 serous adenomas or borderline tumors, 19 endometrioid adenocarcinomas, 22 mucinous adenomas or borderline tumors, 10 mucinous adenocarcinomas, or 3 yolk sac tumors of the ovary. Furthermore, expression of napsin A was not observed in the normal surface epithelium of the ovary, epithelia of the fallopian tubes, squamous epithelium, endocervical epithelium, or the endometrium of the uterus. Therefore, we propose that napsin A is another sensitive and specific marker for distinguishing ovarian clear cell tumors (especially adenocarcinomas) from other ovarian tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Napsin A is a specific marker for ovarian clear cell adenocarcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…WT1 and ER are useful differentiating biomarkers since clear cell carcinoma is negative for both markers, in contradistinction to serous tumors of low malignant potential. 121 Ovarian High-Grade Serous Versus Well-Differentiated or Moderately Differentiated Endometrioid Adenocarcinoma.-WT1, p53, and ARID1A.…”

Section: Ovary the Differential Diagnosis Of Serous Carcinoma Of The mentioning

confidence: 99%

The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders

Kaspar

Crum

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials. Objective To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels. Data Sources Literature review and authors' personal practice experience. Conclusions The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.

show abstract

“…Characteristic cytological features of CCC, including intranuclear inclusions, were also observed in a small number of non‐CCC cases in the present study. Previous reports have similarly observed clear cytoplasm in SC, EC, and mucinous borderline tumors, and hobnail cells have been observed in serous borderline tumors . Therefore, the accuracy of cytological diagnosis of CCC may be improved if cytologists carefully search for the presence of intranuclear inclusions in addition to the common CCC features.…”

Section: Discussionmentioning

confidence: 73%